Tag: KalVista Pharmaceuticals
KalVista Pharmaceuticals ($KALV) Shares Soar 18.20% After FDA Approves EKTERLY Oral HAE Treatment
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) shares surged 18.20% in pre-market trading on Monday, July 7, 2025, hitting $14.16 after FDA approval of HAE candidate....
FDA Approves EKTERLY by KalVista ($KALV) as First Oral On-Demand HAE Treatment
KalVista Pharmaceuticals, Inc. (KALV) announced FDA approval of EKTERLY, a novel plasma kallikrein inhibitor, for treating acute hereditary angioedema attacks in patients aged 12...